



Daily Derivatives

08 January, 2026

DERIVATIVES

Key Indices		
Index	Close	Changes (%)
NIFTY	26140.75	-0.14
SENSEX	84961.14	-0.12
BANKNIFTY	59990.85	-0.21
INDIA VIX	9.95	-0.70

Market Outlook

The Nifty 50 settled at 26,140, marking its third consecutive session of decline. The index remained under pressure again, after slipping below the key 26,200 level. In the derivatives segment, fresh call writing at the 26,200 strike resulted in notable call OI buildup, indicating a near-term upside hurdle. On the downside, the index continues to hold above the 26,000 mark, and sustaining this level keeps the broader bullish bias intact. A decisive move beyond the 26,000–26,200 range will be crucial in determining the next directional move.



TRADE IDEA OF THE DAY -
MARUTI CALL SPREAD

BUY 27JAN 16800 CE SELL 27JAN 17100 CE	
Entry Range	130-135
Target Range	250
Stop Loss	70



Rationale

- The stock continues to trade above its rising trendline, maintaining a higher-high and higher-low formation, which confirms a sustained bullish structure on the daily timeframe.
- Prices are holding above the 20-day and 50-day EMAs, with both averages sloping upward—indicating strong underlying momentum and healthy trend continuation.
- RSI remains above the neutral 50 mark, reflecting strength in buying momentum, while MACD stays in a positive crossover zone, supporting further upside potential.
- Despite the recent minor pullback, the broader setup remains constructive. A hold above the trendline and key moving averages could trigger renewed buying interest, keeping the bullish bias intact.

08 January 2026

Daily Derivatives


NIFTY

Nifty	26237.90
OI (In Lots)	219663
CHANGE IN OI (%)	1.52
PRICE CHANGE (%)	-0.18


BANKNIFTY

Nifty	60170.00
OI (In Lots)	43445
CHANGE IN OI (%)	-9.30
PRICE CHANGE (%)	-0.24


NIFTY OI



BANKNIFTY OI



FII's Activity Index Futures



FII's Long Short Ratio



Long Buildup

Name	Price	Price %	OI	OI%
SWIGGY	363.9	0.46	16786900	21.14
TATAELXSI	5887	9.83	1714300	16.41
MANAPPURAM	320.75	3.85	46053000	11.30
TORNTPHARM	4062.1	3.16	2346000	10.41

Short Buildup

Name	Price	Price %	OI	OI%
SYNGENE	658.6	-0.08	9415000	20.41
CIPLA	1469.9	-4.42	13504125	13.46
PREMIERENE	753.35	-1.36	3322350	12.98
INDHOTEL	716.15	-1.79	28578000	8.61

Breakout Stocks (1 Month High)

Name	LTP	22 DAY HIGH	%
TATAELXSI	5877.5	5513.5	6.6
TITAN	4293.1	4126.9	4.03
TORNTPHARM	4080.3	3945	3.43
SOLARINDS	13391	12986	3.12

Breakdown Stocks (1 Month Low)

Name	LTP	22 DAY LOW	%
HDFCBANK	952.55	961.15	-0.89
POLICYBZR	1726.4	1741.2	-0.85
CIPLA	1471.6	1477	-0.37

08 January 2026

Daily
Derivatives

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	PP*	S1*	S2*
ADANIENT	2291	2308	2267	2250	2226
ADANIPTS	1477	1490	1468	1456	1447
APOLLOHOSP	7519	7590	7417	7346	7244
ASIANPAINT	2842	2875	2822	2789	2768
AXISBANK	1302	1308	1293	1287	1278
BAJAJ-AUTO	9862	9934	9735	9663	9536
BAJAJFINSV	2042	2053	2032	2021	2011
BAJFINANCE	975	982	970	964	959
BEL	418	421	414	411	407
BHARTIARTL	2100	2115	2088	2073	2062
CIPLA	1504	1541	1480	1443	1419
COALINDIA	435	438	429	426	420
DRREDDY	1259	1274	1249	1234	1224
EICHERMOT	7623	7664	7557	7516	7450
ETERNAL	286	291	281	276	272
GRASIM	2868	2900	2849	2817	2798
HCLTECH	1663	1677	1640	1625	1602
HDFCBANK	955	961	951	945	940
HDFCLIFE	778	784	774	768	764
HINDALCO	950	962	943	931	923
HINDUNILVR	2420	2441	2401	2380	2361
ICICIBANK	1437	1446	1421	1411	1395
INDIGO	5024	5098	4972	4898	4846
INFY	1649	1659	1632	1622	1605
ITC	344	347	342	339	336

*R1 - Resistance 1 | *R2 - Resistance 2 | *PP - Pivot Point | *S1 - Support 1 | *S2 - Support 2

08 January 2026

Daily
Derivatives

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	PP*	S1*	S2*
JIOFIN	307	311	302	298	293
JSWSTEEL	1199	1208	1184	1175	1160
KOTAKBANK	2160	2176	2135	2119	2093
LT	4193	4230	4144	4107	4058
M&M	3799	3849	3759	3709	3669
MARUTI	17197	17586	16861	16472	16136
MAXHEALTH	1049	1063	1036	1021	1008
NESTLEIND	1330	1346	1317	1302	1289
NTPC	351	354	349	346	344
ONGC	241	243	240	238	236
POWERGRID	268	271	266	262	260
RELIANCE	1517	1529	1507	1495	1485
SBILIFE	2099	2126	2082	2054	2037
SBIN	1019	1030	1011	1000	993
SHRIRAMFIN	1003	1009	996	990	984
SUNPHARMA	1810	1837	1779	1752	1721
TATACONSUM	1221	1229	1213	1205	1197
TATASTEEL	186	188	184	182	181
TCS	3323	3351	3273	3246	3196
TECHM	1641	1656	1618	1603	1580
TITAN	4323	4373	4262	4213	4152
TMPV	367	371	363	359	355
TRENT	4092	4123	4040	4009	3957
ULTRACEMCO	12263	12343	12171	12091	11999
WIPRO	274	277	269	266	261

*R1 - Resistance 1 | *R2 - Resistance 2 | *PP - Pivot Point | *S1 - Support 1 | *S2 - Support 2

Our Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com

08 January 2026

Daily Derivatives

Before you use this research report, please ensure to go through the disclosure interalia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

S.No.	Statement	Answer	
		Tick Appropriate	
		Yes	No
1.	I/we or any of my/our relative has any financial interest in the subject company? (If answer is yes, nature of interest is given below this table)		No
2.	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of the research report or date of the public appearance?		No
3.	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of the public appearance?		
4.	I/we have received any compensation from the subject company in the past twelve months?		No
5.	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
6.	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
7.	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
8.	I/we have served as an officer, director or employee of the subject company?		No
9.	I/we have been engaged in market making activity for the subject company?		No

2014 is/are as under:

Statements of ownership and material conflicts of interest, compensation – Research Analyst (RA)

Nature of Interest [If answer to f (a) above conflicts is Yes

.....]

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to

Copyright: This document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.